Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EPS (Weighted Average and Diluted) (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.37 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 35.09% year-over-year to -$0.37; the TTM value through Sep 2025 reached -$2.08, up 14.4%, while the annual FY2024 figure was -$2.33, 47.87% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.37 in Q3 2025 per ZNTL's latest filing, up from -$0.38 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.14 in Q1 2024 and bottomed at -$1.85 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.85, with a median of -$0.79 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 113.08% in 2024, then plummeted 578.57% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.87 in 2022, then grew by 12.64% to -$0.76 in 2023, then increased by 13.16% to -$0.66 in 2024, then surged by 43.94% to -$0.37 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.37 in Q3 2025, -$0.38 in Q2 2025, and -$0.67 in Q1 2025.